


# CLINICAL TRIAL

## RECOVER

Neuroophthalmology RED



**This trial does use Clemastine fumarat as a remyelinating agent targeting the muscarinic receptor on oligodendrocytes around the optic nerve.**

Rare Eye Disease concerned by the trial :  
ION, RION, CRION, NMO-ON, MOG-ON.  
Also non-rare diseases: MSON

Status of the trial : Not yet recruiting

Orphan drug recognition : N/A

**Inclusion criteria :** Patients with acute optic neuritis including the rare forms, inclusion within 2 weeks after onset of ION, RION, CRION, etc

**Exclusion criteria :** Marjor ophthalmological disease, myopia >7dpt, simultaneous bilateral ON, pregnancy, other study involvement, (please see protocol for full list)



Inclusion opening date : 01/01/2018



Inclusion closing date (previsional) : 01/01/2020

Children



Adults



### Within ERN-EYE members



Principal location of the trial :

**Moorfields Eye Hospital**

City Road  
London, EC1V 2PD  
UK

[Contact details](#)



Principal investigator name :

Axel Petzold




Other investigators :

Ari Green

**UCSF Sandler Neuroscience Center**

675 Nelson Rising Ln  
San Francisco, CA 94158  
USA



Funder type : Other